NCT04553939 2026-01-02
Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
Henan Cancer Hospital
Phase 2 Completed
Clinical Trials
13 trialsNCT05386888 2025-10-02
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Completed
NCT04518280 2025-01-17
TORCH
Fudan University
Phase 2 Completed
NCT06618014 2025-01-16
NeoTOP
Sun Yat-sen University
Phase 2 Completed
NCT05031494 2025-01-06
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Eucure (Beijing) Biopharma Co., Ltd
Phase 2 Completed
NCT04996758 2024-12-12
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Phase 2 Completed
NCT05060471 2024-12-03
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
Sun Yat-sen University
Phase 2 Completed
NCT04144608 2024-08-09
TOGATHER
Hunan Province Tumor Hospital
Phase 2 Completed
NCT04238169 2024-02-28
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
Xinqiao Hospital of Chongqing
Phase 2 Completed
NCT04217954 2023-06-23
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Peking University
Phase 2 Completed
NCT04044313 2023-06-12
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
Sun Yat-sen University
Phase 2 Completed
NCT04169672 2023-03-02
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Hutchmed
Phase 2 Completed
NCT04005170 2022-08-23
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Phase 2 Completed